Randomisation Program

Call +44 800 138 5451 to contact the RECOVERY team for URGENT problems using the Randomisation Program or for medical advice (in English). All NON-URGENT queries should be emailed to recoverytrial@ndph.ox.ac.uk (for users in the UK, Asia and Africa) or recovery@ecraid.eu (for users in the EU).

	Logged in as: RECOVERY Site
	Section A: Baseline and Eligibility
	Date and time of randomisation: 10 Jan 2025 12:00
Treating clinician A1. Name of treating clinician	
Patient details	
A2. Patient surname	
Patient forename	
A3. NHS number	Tick if not available
A4. What is the patient's date of birth?	
A5. What is the patient's sex? Inclusion criteria	<u> </u>
A6. Has consent been taken in line with the protocol? If answer is No patient cannot be enrolled in the study	•
A6.0.1 How was consent obtained?	
A6.5 Does this patient have pneumonia? See protocol for typical features. If answer is No patient cannot be enrolled in the study	Yes v
A7.1 Does the patient have proven influenza infection?	Yes
A7.1.1 What was influenza rapid antigen (eg, lateral flow) test result?	v
A7.1.2 What was influenza PCR test result?	v
A7.1.3 Does the patient have suspected or confirmed	No V
SARS-CoV-2 infection? A8. Does the patient have any medical history that might,	
In the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial?	
A9. Symptom onset date:	V/ V
A10. Date of hospitalisation:	
A11. Does the patient require oxygen?	V
A12.0 Please select one of the following to describe the current level of ventilation support	
A12.1 Enter latest oxygen saturation measurement (%)	
A12.1.1 Enter latest respiratory rate (breaths/min)	
A12.1.2 Enter latest systolic / diastolic blood pressure (mmHg)	
A12.1.3 Is the patient receiving vasopressors?	
A12.1.4 Does the patient have new or acutely worsened confusion?	
A12.1.5 Does the patient have presumed infective changes on chest imaging (e.g. consolidation or ground glass opacification on plain X-ray, CT or ultrasound)?	·
glass opacincation on plain x-ray, CT or ultrasound)? A12.2.0 Enter latest CRP measurement since admission to hospital (if tested). Please ensure correct units (mg/dL or mg/L) are selected.	mgdt. ▼ □ Tick if not measured □Tick if greater than limit of measurement
Enter 0 if below the limit of measurement A12.2.1 Enter latest procalcitonin measurement since admission to hospital (if tested). (ng/mL or µg/L) (note	□Tick if not measured □Tick if greater than limit of measurement
units are equivalent) Enter 0 if below the limit of measurement A12.3.0 Enter latest creatinine measurement since	
admission to hospital	umoliL ▼ □ Tick if not measured
A12.3.1 Enter latest urea (or blood urea nitrogen) measurement since admission to hospital	mmol/L ▼ □ Tick if not measured
A12.6 Has the patient received an influenza vaccine in the last 9 months?	<u> </u>
Does the patient have any CURRENT comorbidities or A13.1 Diabetes	other medical problems or treatments (present before the current illness)?
A13.2 Heart disease	
A13.3 Chronic lung disease	<u> </u>
A13.4 Active tuberculosis	
A13.5 HIV	~
A13.6 Severe liver disease	~
A13.7 Severe kidney impairment (eGFR<30 or on	~
dialysis) A13.9.0 Does their clinician consider the patient to be	
severely immunocompromised?	
A13.19 Has the patient received a neuraminidase inhibitor (NAI, eg oseltamivir, zanamivir) during this illness, or is NAI treatment considered definitely indicated by the managing doctor?	•
A13.20 Has the patient received baloxavir during this illness, or is baloxavir treatment considered to be definitely indicated by the managing doctor?	
A13.22 Has the patient received systemic corticosteroids (glucocorticoids) for >24h during the current lilness at a dose of >=10 mg prednisolone/day (or >=1.5 mg dexamethasone/day, or >=40 mg hydrocortisone/day), or is corticosteroid treatment at this dose considered to be definitely indicated by the	
managing doctor?	TABLE for the patient (either because the treatment is indicated or contraindicated)?
If you answer Yes it means you think this patient sho A14G.1 Baloxavir marboxii	TABLE for the patient (either because the treatment is indicated or contraindicated)? uld NOT be trandomised to potentially receive this treatment.
A146.1 Baloxavir marboxii A14H.1 Oseltamivir	
A141.1 Dexamethasone	□
Or alternative corticosteroids if pregnant or a neonate. Are the following treatments available?	
A15G.1 Baloxavir marboxil	V
A15H.1 Oseltamivir	v
A15I.1 Dexamethasone Or alternative corticosteroids if pregnant or a neonate.	V
Please sign off this form once complete	
Surname:	
Forename:	
Professional email:	
	Continue